<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101800</url>
  </required_header>
  <id_info>
    <org_study_id>AAUC Study</org_study_id>
    <nct_id>NCT03101800</nct_id>
  </id_info>
  <brief_title>Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis</brief_title>
  <official_title>Low-dose Azathioprine and Allopurinol- Versus Azathioprine Monotherapy in Patients With Ulcerative Colitis: An Investigator-initiated, Open, Multicentre, Parallel-arm, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Hospital Viborg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydvestjysk Hospital Esbjerg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Azathioprine is considered first line immunomodulatory therapy for patients with ulcerative
      colitis. Up to 50% are treatment failures or experience adverse events leading to treatment
      withdrawal. Recent evidence suggests that the combination of allopurinol and low dose
      azathioprine increases the proportion of treatment responders and reduce the risk of adverse
      events.

      Objectives: To evaluate the beneficial and harmful effects of low dose azathioprine and
      allopurinol versus standard azathioprine monotherapy in patients with ulcerative colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator initiated, multicentre, parallel arm, open, randomised controlled trial with
      blinded assessment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Anticipated">December 14, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>52 weeks</time_frame>
    <description>Steroid- and biologic treatment free remission defined as total Mayo score ≤1 without rectal bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to remission</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>52 weeks</time_frame>
    <description>defined as a Mayo score between ≤1 to &lt; 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission</measure>
    <time_frame>52 weeks</time_frame>
    <description>defined as a Mayo subscore of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological mucosal healing</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SIBDQ)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Using Inflammatory Bowel Disease Questionnaire Quality of life (SIBDQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (SHS)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Using the Short health scale (SHS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 6ThioGuanineNucleotiude (6TGN) and clinical mayo score</measure>
    <time_frame>From week 6 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 6TGN and standard blood tests</measure>
    <time_frame>From week 6 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 6TGN and fecal calprotectin</measure>
    <time_frame>From week 6 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 6TGN endoscopic mayo score</measure>
    <time_frame>From week 6 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 6TGN and histological mucosal healing</measure>
    <time_frame>From week 6 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <condition>Colitis Ulcerative Exacerbation</condition>
  <arm_group>
    <arm_group_label>Azathioprine and Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azathioprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine and Allopurinol</intervention_name>
    <description>Low dose Azathioprine in combination with allopurinol 100 mg for 1 year</description>
    <arm_group_label>Azathioprine and Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Standard weight based azathioprine dosage</description>
    <arm_group_label>Azathioprine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to comply with all trial procedures and being available for the duration
             of the trial.

          -  Clinically and histologically verified ulcerative colitis eligible for treatment with
             thiopurines due to steroid dependence (failure to taper steroid or starting a second
             course of systemic steroids within 1 year) or patients with the need for rescue
             therapy with anti-TumorNecrosisFactorα (anti-TNFα)

          -  A sigmoidoscopy or colonoscopy showing active inflammation during the present disease
             flare

          -  Negative stool test for pathogen bacteria incl. Clostridium difficile

          -  Informed consent.

          -  Normal TPMT genotype (homozygous wild-type).

          -  Oral 5-Asa dose stable for 2 weeks

        Exclusion Criteria:

          -  Kidney disease with a GlomerularFiltration Rate (GFR) &lt; 50 ml/min.

          -  Persistent alanine aminotransferase U/L (ALT) twice above upper limit of the normal
             range.

          -  Participation in other interventional clinical trials.

          -  Pregnancy or breastfeeding.

          -  Previous thiopurin treatment.

          -  Previous or current treatment with other biologics than anti-TNFα

          -  Not being able to comply with the study, assessed by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre university hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra B Thomsen</last_name>
      <phone>+4538626540</phone>
      <email>sandra.bohn.thomsen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Sandra Bohn Thomsen</investigator_full_name>
    <investigator_title>MD, Ph.D. candidate</investigator_title>
  </responsible_party>
  <keyword>Azathioprine</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Antimetabolites</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

